Envista Holdings Corporation reiterated its full-year guidance following a strong first quarter, with sales expected to grow between 2% and 4% and adjusted EBITDA between 7% and 13%. The company reported 9.5% core revenue growth in the quarter, which translated into 25% adjusted EBITDA growth and 50% earnings-per-share growth. Barclays reiterated an Overweight rating on the stock on June 11 but lowered the price target to $32 from $34, noting that Envista's end markets continue to stabilize. Envista Holdings is a global medical technology company that develops, manufactures, and markets dental products and equipment under more than 30 brands including Nobel Biocare, Ormco, DEXIS, and Kerr.
Envista Holdings CorpStrong Q1 earnings growth and reiterated guidance, with Barclays maintaining Overweight rating.
Barclays PLC